Literature DB >> 28397423

Corneal Cross-Linking: An Example of Photoinduced Polymerization as a Treatment Modality in Keratoconus.

Magdalena Kubrak-Kisza1, Krystian Jerzy Kisza1, Marta Misiuk-Hojło1.   

Abstract

The cornea is one of the principal refractive elements in the human eye and plays a crucial role in the process of vision. Keratoconus is the most common corneal dystrophy, found mostly among young adults. It is characterized by a reduced number of collagen cross-links in the corneal stroma, resulting in reduced biomechanical stability and an abnormal shape of the cornea. These changes lead to progressive myopia, corneal thinning, central scarring and irregular astigmatism, causing severely impaired vision. Hard contact lenses, photorefractive keratectomy or intracorneal rings are the most common treatment options for refractive error caused by keratoconus. However, these techniques do not treat the underlying cause of the corneal ectasia and therefore are not able to stop the progression of the disease. Riboflavin photoinduced polymerization of corneal collagen, also known as corneal cross-linking (CXL), has been introduced as the first therapy which, by stabilizing the structure of the cornea, prevents the progression of keratoconus. It stiffens the cornea using the photo-sensitizer riboflavin in combination with ultraviolet irradiation. This is a current review of the CXL procedure as a therapy for keratoconus, which relies on photoinduced polymerization of human tissue. We have focused on its biomechanical and physiological influences on the human cornea and have reviewed the previous and current biochemical theories behind cross-linking reactions in the cornea.

Entities:  

Keywords:  cornea; cross-linking; keratoconus; polymerization

Mesh:

Substances:

Year:  2016        PMID: 28397423     DOI: 10.17219/pim/65010

Source DB:  PubMed          Journal:  Polim Med        ISSN: 0370-0747


  1 in total

Review 1.  Therapeutic Ophthalmic Lenses: A Review.

Authors:  N Toffoletto; B Saramago; A P Serro
Journal:  Pharmaceutics       Date:  2020-12-28       Impact factor: 6.321

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.